Recurrent Ovarian Cancer Clinical Trials
51 clinical trials for Recurrent Ovarian Cancer across international registries, including 10 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers — RECRUITING · PHASE1
- CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer — RECRUITING · PHASE1
- Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer — RECRUITING
- To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer — RECRUITING · NA
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression — RECRUITING · PHASE2
- Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study — RECRUITING · NA
- Combination Therapy for Recurrent Ovarian Cancer — RECRUITING · PHASE1
- HS-10502 Combination Treatment in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
- An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer — RECRUITING · PHASE2
- Signal TrAnsduction Pathway Activity Analysis in OVarian cancER — RECRUITING · PHASE2
- Randomized, multicentre, prospective, two-arm, open-label Phase II study to investigate the efficacy and safety of two ZK219477 i.v. infusions (3-hour infusion of 16mg/m2 versus 0.5-hour infusion of 16mg/m2) in patients with recurrent ovarian cancer progressing during, or within 6 months of the end of platinum-based chemotherapy — COMPLETED · PHASE2
- Surgery plus intraperitoneal hyperthermic chemoterapy in platinum-resistant patients with ovarian cancer reccurrence. A Phase II study. — COMPLETED · PHASE2
- A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer — NOT_YET_RECRUITING · PHASE2
- MITO 35b Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. The phase III randomized, open label MITO 35b study: a project of the MITO-MANGO groups. — TERMINATED · PHASE3
- Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. — ACTIVE_NOT_RECRUITING · PHASE2
- Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer — NOT_YET_RECRUITING · PHASE2
- Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer — COMPLETED · PHASE1
- Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer — COMPLETED · PHASE1
- Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Cancer — NOT_YET_RECRUITING · PHASE3
- Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — COMPLETED · PHASE2
- RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL.(REPRAB study- MITO 36) — TERMINATED · PHASE2
- Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi — WITHDRAWN · PHASE2
- A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors — TERMINATED · PHASE1
- Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer — WITHDRAWN · PHASE3
- A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer — OTHER · PHASE1
- Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients — NOT_YET_RECRUITING
- A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer — COMPLETED · PHASE1
- The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab — OTHER · PHASE2
- A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer — COMPLETED · PHASE1
- Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer — OTHER · PHASE3
- Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer — COMPLETED · PHASE1
- Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer — WITHDRAWN · PHASE1
- Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer — COMPLETED · PHASE2
- Niraparib Plus Anlotinib for Recurrent Ovarian Cancer — OTHER · PHASE2
- Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer — OTHER · PHASE1
- Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer — COMPLETED · PHASE1
- Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer — COMPLETED · PHASE1
- H.O.P.E: Helping Ovarian Cancer Patients Cope — COMPLETED · NA
- Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer — COMPLETED · PHASE1
- Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma — COMPLETED · PHASE2
- Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer — OTHER · PHASE2
- An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer — COMPLETED
- Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer — OTHER
- A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers — TERMINATED · PHASE2
- Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment — TERMINATED · PHASE4
- LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma — WITHDRAWN · PHASE1
- Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer — COMPLETED · PHASE1
- Interactive Educational Website for Women With Ovarian Cancer & Caregivers — COMPLETED · PHASE1
- Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer — COMPLETED · PHASE1
Refine this search